Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Ann Rheum Dis. 2019 Feb;78(2):171-178. DOI 10.1136/annrheumdis-2018-213271
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2019 Feb;78(2):171-178. DOI 10.1136/annrheumdis-2018-213271
J Rheumatol. 2019 Jan;46(1):7-18. DOI: 10.3899/jrheum.171361
Clinical Rheumatology 2018;37:2381–90 DOI 10.1007/s10067-018-4221-0
Ann Rheum Dis. 2018 Jul;77(7):988-995. DOI 10.1136/annrheumdis-2017-212461
ADV Ther 2018; 35(10):1525–63 DOI: 10.1007/s12325-018-0757-2
Exp Rev Clin Immunol 2018 Nov;14(11):945-956. DOI: 10.1080/1744666X.2018.1504678
Drug Safety 2018 Jul;41(7):645–53
Lancet 2018;391:2513–24
RMD Open. 2018 May 8;4(1):e000662. DOI: 10.1136/rmdopen-2018-000662